FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295015003> ?p ?o ?g. }

• W4295015003 endingPage "164" @default.
• W4295015003 startingPage "153" @default.
• W4295015003 abstract "•We aimed to determine the capacity of low-dose IL-2 to promote allograft tolerance in individuals on tacrolimus monotherapy.•Low-dose IL-2 expanded circulating Tregs but did not increase donor-specific Tregs or promote their trafficking to the liver.•Treatment elicited an IFNγ-orchestrated inflammatory response in the liver with accumulation of lympho-monocytic cells in sinusoidal areas.•Low-dose IL-2 was not conducive to liver allograft tolerance and may have increased the risk of T-cell-mediated rejection. Background & AimsCD4+CD25+Foxp3+ regulatory T cells (Tregs) are essential to maintain immunological tolerance and have been shown to promote liver allograft tolerance in both rodents and humans. Low-dose IL-2 (LDIL-2) can expand human endogenous circulating Tregs in vivo, but its role in suppressing antigen-specific responses and promoting Treg trafficking to the sites of inflammation is unknown. Likewise, whether LDIL-2 facilitates the induction of allograft tolerance has not been investigated in humans.MethodsWe conducted a clinical trial in stable liver transplant recipients 2–6 years post-transplant to determine the capacity of LDIL-2 to suppress allospecific immune responses and allow for the complete discontinuation of maintenance immunosuppression (ClinicalTrials.gov NCT02949492). One month after LDIL-2 was initiated, those exhibiting at least a 2-fold increase in circulating Tregs gradually discontinued immunosuppression over a 4-month period while continuing LDIL-2 for a total treatment duration of 6 months.ResultsAll participants achieved a marked and sustained increase in circulating Tregs. However, this was not associated with the preferential expansion of donor-reactive Tregs and did not promote the accumulation of intrahepatic Tregs. Furthermore, LDIL-2 induced a marked IFNγ-orchestrated transcriptional response in the liver even before immunosuppression weaning was initiated. The trial was terminated after the first 6 participants failed to reach the primary endpoint owing to rejection requiring reinstitution of immunosuppression.ConclusionsThe expansion of circulating Tregs in response to LDIL-2 is not sufficient to control alloimmunity and to promote liver allograft tolerance, due, at least in part, to off-target effects that increase liver immunogenicity. Our trial provides unique insight into the mechanisms of action of immunomodulatory therapies such as LDIL-2 and their limitations in promoting alloantigen-specific effects and immunological tolerance.Clinical Trials RegistrationThe study is registered at ClinicalTrials.gov (NCT02949492).Impact and implicationsThe administration of low-dose IL-2 is an effective way of increasing the number of circulating regulatory T cells (Tregs), an immunosuppressive lymphocyte subset that is key for the establishment of immunological tolerance, but its use to promote allograft tolerance in the setting of clinical liver transplantation had not been explored before. In liver transplant recipients on tacrolimus monotherapy, low-dose IL-2 effectively expanded circulating Tregs but did not increase the number of Tregs with donor specificity, nor did it promote their trafficking to the transplanted liver. Low-dose IL-2 did not facilitate the discontinuation of tacrolimus and elicited, as an off-target effect, an IFNγ-orchestrated inflammatory response in the liver that resembled T cell-mediated rejection. These results, supporting an unexpected role for IL-2 in regulating the immunogenicity of the liver, highlight the need to carefully evaluate systemic immunoregulatory strategies with investigations that are not restricted to the blood compartment and involve target tissues such as the liver. CD4+CD25+Foxp3+ regulatory T cells (Tregs) are essential to maintain immunological tolerance and have been shown to promote liver allograft tolerance in both rodents and humans. Low-dose IL-2 (LDIL-2) can expand human endogenous circulating Tregs in vivo, but its role in suppressing antigen-specific responses and promoting Treg trafficking to the sites of inflammation is unknown. Likewise, whether LDIL-2 facilitates the induction of allograft tolerance has not been investigated in humans. We conducted a clinical trial in stable liver transplant recipients 2–6 years post-transplant to determine the capacity of LDIL-2 to suppress allospecific immune responses and allow for the complete discontinuation of maintenance immunosuppression (ClinicalTrials.gov NCT02949492). One month after LDIL-2 was initiated, those exhibiting at least a 2-fold increase in circulating Tregs gradually discontinued immunosuppression over a 4-month period while continuing LDIL-2 for a total treatment duration of 6 months. All participants achieved a marked and sustained increase in circulating Tregs. However, this was not associated with the preferential expansion of donor-reactive Tregs and did not promote the accumulation of intrahepatic Tregs. Furthermore, LDIL-2 induced a marked IFNγ-orchestrated transcriptional response in the liver even before immunosuppression weaning was initiated. The trial was terminated after the first 6 participants failed to reach the primary endpoint owing to rejection requiring reinstitution of immunosuppression. The expansion of circulating Tregs in response to LDIL-2 is not sufficient to control alloimmunity and to promote liver allograft tolerance, due, at least in part, to off-target effects that increase liver immunogenicity. Our trial provides unique insight into the mechanisms of action of immunomodulatory therapies such as LDIL-2 and their limitations in promoting alloantigen-specific effects and immunological tolerance." @default.
• W4295015003 created "2022-09-09" @default.
• W4295015003 creator A5010455658 @default.
• W4295015003 creator A5011166254 @default.
• W4295015003 creator A5011584155 @default.
• W4295015003 creator A5012031442 @default.
• W4295015003 creator A5014937187 @default.
• W4295015003 creator A5017174323 @default.
• W4295015003 creator A5020078397 @default.
• W4295015003 creator A5021297806 @default.
• W4295015003 creator A5021419708 @default.
• W4295015003 creator A5022963653 @default.
• W4295015003 creator A5029937461 @default.
• W4295015003 creator A5030984910 @default.
• W4295015003 creator A5033624012 @default.
• W4295015003 creator A5051675830 @default.
• W4295015003 creator A5054080684 @default.
• W4295015003 creator A5060724793 @default.
• W4295015003 creator A5063315684 @default.
• W4295015003 creator A5065099795 @default.
• W4295015003 creator A5067553313 @default.
• W4295015003 creator A5069395837 @default.
• W4295015003 creator A5078940172 @default.
• W4295015003 creator A5084713803 @default.
• W4295015003 date "2023-01-01" @default.
• W4295015003 modified "2023-10-18" @default.
• W4295015003 title "Low dose interleukin-2 selectively expands circulating regulatory T cells but fails to promote liver allograft tolerance in humans" @default.
• W4295015003 cites W1970246068 @default.
• W4295015003 cites W1978586979 @default.
• W4295015003 cites W2026458427 @default.
• W4295015003 cites W2037225699 @default.
• W4295015003 cites W2043016325 @default.
• W4295015003 cites W2051056012 @default.
• W4295015003 cites W2077490433 @default.
• W4295015003 cites W2084274600 @default.
• W4295015003 cites W2085106134 @default.
• W4295015003 cites W2086030126 @default.
• W4295015003 cites W2106107076 @default.
• W4295015003 cites W2126897233 @default.
• W4295015003 cites W2130778427 @default.
• W4295015003 cites W2132976465 @default.
• W4295015003 cites W2143967688 @default.
• W4295015003 cites W2147557220 @default.
• W4295015003 cites W2175695425 @default.
• W4295015003 cites W2284630235 @default.
• W4295015003 cites W2326365518 @default.
• W4295015003 cites W2477823035 @default.
• W4295015003 cites W2488042065 @default.
• W4295015003 cites W2621829867 @default.
• W4295015003 cites W2793084066 @default.
• W4295015003 cites W2801007060 @default.
• W4295015003 cites W2888344630 @default.
• W4295015003 cites W2898591181 @default.
• W4295015003 cites W2899501401 @default.
• W4295015003 cites W2901041673 @default.
• W4295015003 cites W2902898201 @default.
• W4295015003 cites W2912432695 @default.
• W4295015003 cites W2978131638 @default.
• W4295015003 cites W3039341768 @default.
• W4295015003 cites W3183662835 @default.
• W4295015003 cites W3184999299 @default.
• W4295015003 cites W3197123215 @default.
• W4295015003 doi "https://doi.org/10.1016/j.jhep.2022.08.035" @default.
• W4295015003 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36087863" @default.
• W4295015003 hasPublicationYear "2023" @default.
• W4295015003 type Work @default.
• W4295015003 citedByCount "15" @default.
• W4295015003 countsByYear W42950150032022 @default.
• W4295015003 countsByYear W42950150032023 @default.
• W4295015003 crossrefType "journal-article" @default.
• W4295015003 hasAuthorship W4295015003A5010455658 @default.
• W4295015003 hasAuthorship W4295015003A5011166254 @default.
• W4295015003 hasAuthorship W4295015003A5011584155 @default.
• W4295015003 hasAuthorship W4295015003A5012031442 @default.
• W4295015003 hasAuthorship W4295015003A5014937187 @default.
• W4295015003 hasAuthorship W4295015003A5017174323 @default.
• W4295015003 hasAuthorship W4295015003A5020078397 @default.
• W4295015003 hasAuthorship W4295015003A5021297806 @default.
• W4295015003 hasAuthorship W4295015003A5021419708 @default.
• W4295015003 hasAuthorship W4295015003A5022963653 @default.
• W4295015003 hasAuthorship W4295015003A5029937461 @default.
• W4295015003 hasAuthorship W4295015003A5030984910 @default.
• W4295015003 hasAuthorship W4295015003A5033624012 @default.
• W4295015003 hasAuthorship W4295015003A5051675830 @default.
• W4295015003 hasAuthorship W4295015003A5054080684 @default.
• W4295015003 hasAuthorship W4295015003A5060724793 @default.
• W4295015003 hasAuthorship W4295015003A5063315684 @default.
• W4295015003 hasAuthorship W4295015003A5065099795 @default.
• W4295015003 hasAuthorship W4295015003A5067553313 @default.
• W4295015003 hasAuthorship W4295015003A5069395837 @default.
• W4295015003 hasAuthorship W4295015003A5078940172 @default.
• W4295015003 hasAuthorship W4295015003A5084713803 @default.
• W4295015003 hasBestOaLocation W42950150031 @default.
• W4295015003 hasConcept C203014093 @default.
• W4295015003 hasConcept C2776090121 @default.
• W4295015003 hasConcept C2777702733 @default.
• W4295015003 hasConcept C2778296632 @default.
• W4295015003 hasConcept C2779727006 @default.

• next